Nivolumab conferred a statistically significant and clinically meaningful improvement in recurrence-free survival vs. placebo among patients with completely resected stage IIB or IIC melanoma, according to the agent’s manufacturer.
2022
Encorafenib /Binimetinib Showcases Sustained Responses in BRAF V600–Mutant Melanoma
A 5-year follow-up of the COLOMBUS trial showed that encorafenib plus binimetinib continued to provide clinical benefit for patients with melanoma harboring a BRAF V600 mutation.
Adjuvant Nivolumab Reduces Risk of Recurrence or Death by 58% in Select Stage IIB or IIC Melanoma
Adjuvant treatment with nivolumab (Opdivo) resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) over placebo in patients with completely resected stage IIB or IIC melanoma, meeting the primary end point of the phase 3 CheckMate-76K trial (NCT04099251).
Immunotherapy and BRAF-Targeted Therapy Fill Expanded Roles Across Melanoma
Immunotherapy and targeted therapy combinations containing BRAF and MEK inhibitors have carved out roles in different settings of melanoma, which has given clinicians different options for treatment sequencing, according to faculty from an OncLive® Institutional Perspectives in Cancer webinar on skin cancer.